Humana Inc, Louisville, Kentucky.
Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
JAMA Health Forum. 2022 Sep 2;3(9):e222935. doi: 10.1001/jamahealthforum.2022.2935.
Low-value care in the Medicare program is prevalent, costly, potentially harmful, and persistent. Although Medicare Advantage (MA) plans can use managed care strategies not available in traditional Medicare (TM), it is not clear whether this flexibility is associated with lower rates of low-value care.
To compare rates of low-value services between MA and TM beneficiaries and explore how elements of insurance design present in MA are associated with the delivery of low-value care.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study analyzed beneficiaries enrolled in MA and TM using claims data from a large, national MA insurer and a random 5% sample of TM beneficiaries. The study period was January 1, 2017, through December 31, 2019. All analyses were conducted from July 2021 to March 2022.
Enrollment in MA vs TM.
Low-value care was assessed using 26 claims-based measures. Regression models were used to estimate the association between MA enrollment and rates of low-value services while controlling for beneficiary characteristics. Stratified analyses explored whether network design, product design, value-based payment, or utilization management moderated differences in low-value care between MA and TM beneficiaries and among MA beneficiaries.
Among a study population of 2 470 199 Medicare beneficiaries (mean [SD] age, 75.6 [7.0] years; 1 346 777 [54.5%] female; 229 107 [9.3%] Black and 2 126 353 [86.1%] White individuals), 1 527 763 (61.8%) were enrolled in MA and 942 436 (38.2%) were enrolled in TM. Beneficiaries enrolled in MA received 9.2% (95% CI, 8.5%-9.8%) fewer low-value services in 2019 than TM beneficiaries (23.1 vs 25.4 total low-value services per 100 beneficiaries). Although MA beneficiaries enrolled in health management organization and preferred provider organization products received fewer low-value services than TM beneficiaries, the difference was largest for those enrolled in health management organization products (2.6 fewer [95% CI, 2.4-2.8] vs 2.1 fewer [95% CI, 1.9-2.3] services per 100 beneficiaries, respectively). Across primary care payment arrangements, MA beneficiaries received fewer low-value services than TM beneficiaries, with the largest difference observed for MA beneficiaries whose primary care physicians were reimbursed within 2-sided risk arrangements.
In this cross-sectional study of Medicare beneficiaries, those enrolled in MA had lower rates of low-value care than those enrolled in TM; elements of insurance design present in the MA program and absent in TM were associated with reduction in low-value care.
医疗保险计划中存在大量低价值的医疗服务,这些服务不仅费用高昂,而且可能对患者造成伤害,但却持续存在。尽管医疗保险优势(MA)计划可以使用传统医疗保险(TM)中没有的管理式医疗策略,但目前尚不清楚这种灵活性是否与低价值医疗服务的低发生率有关。
比较 MA 和 TM 受益人的低价值服务率,并探讨 MA 中存在的保险设计要素与低价值医疗服务的提供之间的关系。
设计、设置和参与者:本横断面研究使用大型 MA 保险公司的索赔数据和 TM 的随机 5%抽样受益人的数据,对 MA 和 TM 中的受益人进行了分析。研究期间为 2017 年 1 月 1 日至 2019 年 12 月 31 日。所有分析均于 2021 年 7 月至 2022 年 3 月进行。
MA 与 TM 的参保情况。
使用 26 项基于索赔的措施评估低价值护理。回归模型用于估计 MA 参保与低价值服务率之间的关联,同时控制受益人的特征。分层分析探讨了网络设计、产品设计、基于价值的支付或利用管理是否调节了 MA 和 TM 受益人与 MA 受益人的低价值护理差异,以及 MA 受益人的低价值护理差异。
在一项纳入 2470199 名 Medicare 受益人的研究人群中(平均[标准差]年龄为 75.6[7.0]岁;1346777[54.5%]为女性;229107[9.3%]为黑人,2126353[86.1%]为白人),1527763(61.8%)人参加了 MA,942436(38.2%)人参加了 TM。与 TM 受益人相比,2019 年参加 MA 的受益人接受的低价值服务少 9.2%(95%CI,8.5%-9.8%;每 100 名受益人中有 23.1 项[95%CI,25.4 项]与 25.4 项)。尽管参加健康管理组织和首选医疗服务组织产品的 MA 受益人接受的低价值服务比 TM 受益人少,但参加健康管理组织产品的受益人的差异最大(分别减少 2.6 项[95%CI,2.4-2.8]和 2.1 项[95%CI,1.9-2.3])。在初级保健支付安排方面,与 TM 受益人相比,MA 受益人接受的低价值服务较少,其中最大的差异发生在初级保健医生的报酬在双边风险安排内的 MA 受益人中。
在这项对 Medicare 受益人的横断面研究中,参加 MA 的受益人的低价值护理率低于参加 TM 的受益人的低价值护理率;MA 计划中存在的保险设计要素和 TM 中不存在的要素与低价值护理的减少有关。